Clinique Cisto ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  9.2% 17.2% 10.2% 8.9% 11.9%  
Credit score (0-100)  28 9 23 27 19  
Credit rating  BB BB BB BB BB  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 -0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Gross profit  184 114 318 562 588  
EBITDA  117 -97.6 56.3 33.3 -220  
EBIT  112 -106 45.0 26.7 -235  
Pre-tax profit (PTP)  111.9 -106.4 44.3 26.2 -252.2  
Net earnings  94.8 -106.4 44.3 13.7 -242.1  
Pre-tax profit without non-rec. items  112 -106 44.3 26.2 -252  

 
See the entire income statement

Balance sheet (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Tangible assets total  9.4 34.4 23.1 16.5 78.2  
Shareholders equity total  99.1 -7.3 36.9 50.6 -191  
Interest-bearing liabilities  62.7 52.6 81.5 68.8 405  
Balance sheet total (assets)  231 206 259 245 400  

Net Debt  -52.3 -21.7 -16.4 -3.7 399  
 
See the entire balance sheet

Volume 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  184 114 318 562 588  
Gross profit growth  309.4% -37.9% 178.1% 77.1% 4.6%  
Employees  1 1 1 2 2  
Employee growth %  0.0% 0.0% 0.0% 100.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  231 206 259 245 400  
Balance sheet change%  77.2% -10.8% 25.7% -5.3% 63.3%  
Added value  116.6 -97.6 56.3 38.0 -220.0  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  -9 17 -23 -13 46  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  1.0 -1.0 1.0 2.0 -1.0  

Profitability 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  60.9% -92.5% 14.2% 4.7% -40.0%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  60.1% -47.6% 19.1% 10.6% -56.2%  
ROI %  77.3% -98.6% 52.6% 22.4% -89.6%  
ROE %  82.6% -69.8% 36.5% 31.3% -107.4%  

Solidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Equity ratio %  42.9% -3.4% 14.3% 20.7% -32.4%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  -44.9% 22.2% -29.1% -11.1% -181.5%  
Gearing %  63.3% -716.4% 220.6% 135.8% -211.6%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 1.4% 1.1% 0.6% 7.1%  

Liquidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Quick Ratio  0.9 0.3 0.4 0.4 0.0  
Current Ratio  1.6 0.8 1.0 1.1 0.5  
Cash and cash equivalent  115.1 74.3 97.9 72.4 5.9  

Capital use efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  80.1 -51.3 4.2 25.0 -324.1  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales / employee  0 0 0 0 0  
Added value / employee  117 -98 56 19 -110  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  117 -98 56 17 -110  
EBIT / employee  112 -106 45 13 -118  
Net earnings / employee  95 -106 44 7 -121